CIMBAN
"CIMBAN" is a word mark owned by Camena Bioscience Limited, filed at the USPTO on May 20, 2024. It is registered and covers classes 1 and 42.
- Status
- Registered
- Since May 27, 2025
- Filed
- May 20, 2024
- Registered
- May 27, 2025
- Priority date
- May 10, 2024
- Claimed from United Kingdom
- Application no.
- 98558902
- Registration no.
- 7806705
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 2 classes
Who owns CIMBAN
The owner and representative on file with the office.
Owner
Camena Bioscience Limited
SAFFRON WALDEN, Essex, United Kingdom
Representative
Jeffrey H. Greene
Foley & Lardner LLP
What the mark covers
The products and services CIMBAN is filed for, grouped by Nice class.
Chemicals for use in the biochemical and chemical industry; Chemical substances for use in the production of drugs, pharmaceuticals and antibodies; Active chemical ingredients for use in the production of drugs, pharmaceuticals and antibodies; DNA nucleotides, RNA nucleotides, XNA nucleotides, biotechnologically formed genes, oligonucleotides and proteins for scientific and research use; Nucleic acids comprising synthetic nucleotides for scientific and research use; Synthetic DNA nucleotides, synthetic RNA nucleotides, synthetic genes being biotechnologically formed genes, synthetic oligonucleotides and synthetic proteins for laboratory, scientific and industrial use; Chemical preparations, namely, synthetic enzymes, gene editing enzymes, DNA nucleotides, RNA nucleotides, XNA nucleotides, biotechnologically formed genes, oligonucleotides and proteins for laboratory, scientific and industrial purposes; Synthetic DNA and RNA nucleotides for scientific and medical research; synthetic DNA nucleotides, RNA nucleotides, XNA nucleotides, biotechnologically formed genes, oligonucleotides and proteins for use in medical biologics and therapeutics; Molecular biology research tools in the nature of chemical, biological and biochemical reagents used for the synthesis of DNA, RNA, XNA, oligonucleotides, genes and proteins.
Consultancy in relation to biochemistry and biotechnology; Research and development in the field of biotechnology and synthetic biology; Biological analysis; Biotechnological research relating to enzymatic synthesis; Provision of gene synthesis solutions, namely, creating and modifying genetic sequences for scientific purposes; Development and test of enzyme production methods; Evaluations, estimates, research and preparing related reports and technical documentation of genetic materials all in the field of enzymatic production; Scientific and technological services in the field of biotechnology consisting of the development of innovative processes to produce synthetic genes; Genetic engineering, namely, production of nucleic acid sequences; Research and development services relating to the creation of synthetic nucleic acid sequences; Genetic engineering services being the design, development, and testing of synthetic gene sequences; Design, development, rental and leasing of test and collection devices and kits for analysis of nucleic acid sequences, nucleic acids and genetic materials; Genetic engineering services, namely, manufacture of synthetic DNA, RNA, genes and oligonucleotides for others; Genetic engineering and scientific laboratory services being the design, development and testing of synthetic gene sequences in complex gene production; Research and development services in the field of nucleic acid synthesis technology; Technical consulting in the field of biotechnology; Genetic engineering, namely, production of complex gene sequences; Consultancy, advisory and information services related to the aforementioned services; Software-as-a-Service (SaaS) services featuring software with a bioinformatics algorithm for use in designing gene assembly paths; Platform-as-a Service (PaaS) services featuring software platforms with a bioinformatics algorithm for use in designing gene assembly paths.
What has happened so far
Steps recorded by the USPTO, newest first.
- Notice of registration confirmation emailed
- Registered-principal register
- Official gazette publication confirmation e-mailed
- Published for opposition
- Notification of notice of publication e-mailed
- Approved for pub - principal register
- Teas/email correspondence entered
- Correspondence received in law office
- Teas response to office action received
- Notification of non-final action e-mailed
5 earlier steps on the official record.
About CIMBAN
Who owns the trademark "CIMBAN"?
The USPTO trademark "CIMBAN" (application 98558902) is owned by Camena Bioscience Limited.
What is the status of "CIMBAN"?
Its status at the USPTO is: registered.
When was "CIMBAN" registered?
It was registered on May 27, 2025.
Get this data via the API
Everything on this page comes from the Signa API. Pull CIMBAN and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2cea-1ed2-7089-9ae8-8da0e19e15e9
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2cea-1ed2-7089-9ae8-8da0e19e15e9",
"object": "trademark",
"mark_text": "CIMBAN",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "US",
"application_number": "98558902",
"filing_date": "2024-05-20",
"nice_classes": [
1,
42
],
"owners": [
{
"name": "Camena Bioscience Limited",
"entity_id": null
}
]
}